Skip to content

Home Search Authors Pakistan News Saved

SciRah

SciRah does not host or store research papers. Results come live from free, official scholarly APIs, and every paper links back to its original source.

Data sources

OpenAlex
Semantic Scholar
Crossref
CORE
arXiv
PubMed

Privacy policy Terms of service

S. Rafii · SciRah

Researcher profile · Semantic Scholar

S. Rafii

Share profile

S. Rafii — researcher profile on SciRah

h-index: 15
Works: 49
Citations: 1,938

Most-cited papers

Safety and Efficacy of Durvalumab (MEDI4736), an Anti-Programmed Cell Death Ligand-1 Immune Checkpoint Inhibitor, in Patients With Advanced Urothelial Bladder Cancer.
C. Massard, M. Gordon, Sunil Sharma, S. Rafii +15 more
2016Journal of Clinical Oncology725 citations Open access
Semantic Scholar
Phase I, Dose-Escalation, Two-Part Trial of the PARP Inhibitor Talazoparib in Patients with Advanced Germline BRCA1/2 Mutations and Selected Sporadic Cancers
J. de Bono, R. Ramanathan, L. Mina, R. Chugh +12 more
2017Cancer Discovery373 citations Open access
Semantic Scholar
BGCS uterine cancer guidelines: Recommendations for practice.
S. Sundar, J. Bálega, E. Crosbie, A. Drake +16 more
2017European Journal of Obstetrics, Gynecology, and Reproductive Biology140 citations Open access
Semantic Scholar
A potential role for the XRCC2 R188H polymorphic site in DNA-damage repair and breast cancer.
S. Rafii, Paul O'Regan, G. Xinarianos, Iman A. F. Azmy +5 more
2002Human Molecular Genetics140 citations
Semantic Scholar
Tetrathiomolybdate-associated copper depletion decreases circulating endothelial progenitor cells in women with breast cancer at high risk of relapse.
S. Jain, J. Cohen, M. Ward, N. Kornhauser +16 more
2013Annals of Oncology91 citations Open access
Semantic Scholar
Five Polymorphisms and Breast Cancer Risk: Results from the Breast Cancer Association Consortium
M. Gaudet, R. Milne, A. Cox, N. Camp +111 more
2009Cancer Epidemiology, Biomarkers and Prevention72 citations Open access
Semantic Scholar
A phase I/II study of epertinib plus trastuzumab with or without chemotherapy in patients with HER2-positive metastatic breast cancer
I. Macpherson, P. Spiliopoulou, S. Rafii, M. Saggese +10 more
2019Breast Cancer Research45 citations Open access
Semantic Scholar
Safety and antitumor activity of the PARP inhibitor BMN673 in a phase 1 trial recruiting metastatic small-cell lung cancer (SCLC) and germline BRCA-mutation carrier cancer patients.
Z. Wainberg, S. Rafii, R. Ramanathan, L. Mina +10 more
201442 citations
Semantic Scholar
Current Status of CRISPR/Cas9 Application in Clinical Cancer Research: Opportunities and Challenges
S. Rafii, E. Tashkandi, N. Bukhari, H. Al-Shamsi
2022Cancers39 citations Open access
Semantic Scholar
Mitotic defects in XRCC3 variants T241M and D213N and their relation to cancer susceptibility.
A. Lindh, S. Rafii, N. Schultz, A. Cox +1 more
2006Human Molecular Genetics39 citations Open access
Semantic Scholar
Higher risk of infections with PI3K-AKT-mTOR pathway inhibitors in patients with advanced solid tumors on Phase I clinical trials
S. Rafii, D. Roda, E. Geuna, B. Jímenez +7 more
2015Clinical Cancer Research35 citations Open access
Semantic Scholar
Complications of hyperglycaemia with PI3K–AKT–mTOR inhibitors in patients with advanced solid tumours on Phase I clinical trials
E. Geuna, D. Roda, S. Rafii, B. Jímenez +8 more
2015British Journal of Cancer31 citations Open access
Semantic Scholar
Baseline clinical predictors of antitumor response to the PARP inhibitor olaparib in germline BRCA1/2 mutated patients with advanced ovarian cancer
S. Rafii, C. Gourley, Rajiv Kumar, E. Geuna +13 more
2017OncoTarget28 citations Open access
Semantic Scholar
Breast Cancer in the United Arab Emirates
H. Al-Shamsi, Nadia Abdelwahed, Aydah Al-Awadhi, Mohamed Albashir +42 more
2023JCO Global Oncology25 citations Open access
Semantic Scholar
A naturally occurring mutation in an ATP-binding domain of the recombination repair gene XRCC3 ablates its function without causing cancer susceptibility.
S. Rafii, A. Lindblom, M. Reed, M. Meuth +1 more
2003Human Molecular Genetics17 citations
Semantic Scholar
Safety and efficacy of durvalumab (MEDI4736), a PD-L1 antibody, in urothelial bladder cancer.
C. Massard, M. Gordon, Sunil Sharma, S. Rafii +14 more
201615 citations
Semantic Scholar
A Proposal for a National Cancer Control Plan for the UAE: 2022–2026
H. Al-Shamsi, Amin M Abyad, S. Rafii
2022Clinics and Practice14 citations Open access
Semantic Scholar
A potential role for the XRCC 2 R 188 H polymorphic site in DNA-damage repair and breast cancer
S. Rafii, Paul O'Regan, G. Xinarianos, Iman A. F. Azmy +5 more
200212 citations
Semantic Scholar
Clinical factors of response in patients with advanced ovarian cancer participating in early phase clinical trials.
A. George, R. Kristeleit, S. Rafii, C. Michie +13 more
2017European Journal of Cancer11 citations Open access
Semantic Scholar
Uterine Cancer Guidelines : Recommendations for Practice
S. Sundar, J. Bálega, E. Crosbie, A. Drake +28 more
20179 citations
Semantic Scholar
Effect of multiple-dose osimertinib (AZD9291) on the pharmacokinetics (PK) of simvastatin and rosuvastatin.
R. Harvey, N. Isambert, S. Rafii, J. Vansteenkiste +6 more
20168 citations
Semantic Scholar
Abstract OT2-07-03: IMpassion031: A phase III study comparing neoadjuvant atezolizumab vs placebo in combination with nab-paclitaxel–based chemotherapy in early triple-negative breast cancer (TNBC)
E. Mittendorf, C. Barrios, N. Harbeck, D. Miles +5 more
20185 citations
Semantic Scholar
TARGET trial: Molecular profiling of circulating tumour DNA to stratify patients to early phase clinical trials.
M. Krebs, C. Dive, E. Dean, D. Rothwell +14 more
20164 citations
Semantic Scholar
Narrative review of novel chemotherapeutic agents in management of ovarian cancer
S. Rafii
2021Gynecology and Pelvic Medicine2 citations Open access
Semantic Scholar
Randomized phase II trial of venetoclax + fulvestrant versus fulvestrant in estrogen receptor+, HER2– locally advanced or metastatic breast cancer following recurrence or progression during or after a CDK4/6 inhibitor: VERONICA.
G. Lindeman, A. Bardia, R. Bowen, Aulde Fléchais +4 more
2019Journal of Clinical Oncology2 citations
Semantic Scholar
212TiPIMpassion031: A phase III study comparing neoadjuvant atezolizumab (atezo) vs placebo in combination with anthracycline/nab-paclitaxel (nab-pac)–based chemotherapy in early triple-negative breast cancer (eTNBC)
E. Mittendorf, C. Barrios, N. Harbeck, K. Jung +6 more
20172 citations Open access
Semantic Scholar
Early neutrophil to lymphocyte ratio dynamics to predict progression free survival in patients treated with immune-checkpoint inhibitors.
M. Moschetta, B. Kasenda, G. Mak, M. Voskoboynik +4 more
20162 citations
Semantic Scholar
Dynamics of neutrophil to lymphocyte ratio (NLR) predict effectiveness of PD1/PDL1 inhibition
M. Moschetta, B. Kasenda, G. Mak, M. Voskoboynik +4 more
20162 citations Open access
Semantic Scholar
What clinical factors influence advanced BRCA1/2 mutant ovarian cancer patient (BMOC pt) outcomes to poly(ADP-ribose) polymerase inhibitor (PARPi) treatment?
S. Rafii, C. Gourley, Joo Ern Ang, Rajiv Kumar +16 more
20152 citations
Semantic Scholar
TAX-TORC: A phase I trial of the combination of AZD2014 (dual mTORC1/mTORC2 inhibitor) and weekly paclitaxel in patients with solid tumors.
D. Roda, Han H. Wong, E. Geuna, S. Rafii +16 more
20142 citations
Semantic Scholar
Is uterine serous carcinoma a part of hereditary breast cancer syndrome
S. Rafii, P. Dawson, Sarah Williams, J. Pascoe +2 more
20132 citations
Semantic Scholar
The role of maintenance pemetrexed in the treatment of non-small-cell lung cancer.
S. Rafii, M. Cullen
2010Lung Cancer2 citations Open access
Semantic Scholar
Abstract P4-21-08: A phase I/II of S-222611, a reversible EGFR and HER2 inhibitor, combined with trastuzumab +/- chemotherapy in patients with HER2-positive metastatic breast cancer
S. Rafii, I. Macpherson, R. Baird, M. Saggese +10 more
20171 citations
Semantic Scholar
SELECT-3: A phase I study of selumetinib in combination with platinum doublet chemotherapy for advanced NSCLC in the first-line setting
E. Dean, Nicola Steele, H. Arkenau, F. Blackhall +11 more
20161 citations Open access
Semantic Scholar
33. Current Status and Future Direction of PARP Inhibition in Cancer Therapy
S. Rafii, S. Kaye, Susana Banerjee
20151 citations
Semantic Scholar
Neo-escape: Neoadjuvant extended sequential chemotherapy with adjuvant postoperative treatment for epithelial nonmucinous advanced inoperable peritoneal malignancy.
C. Poole, A. Marshall, Helen B Higgins, J. Fletcher +8 more
20121 citations Open access
Semantic Scholar
Sixth Annual Mediclinic Middle East Research Conference
Zakaullah Khan, H. van Eck, Rakshinda Mujeeb Research, P. East +42 more
2023Medicine0 citations Open access
Semantic Scholar
BRAF +/- MEK inhibition in patients (pts) with BRAF-mutant (mut) metastatic colorectal cancer (mCRC): The Sarah Cannon Research Institute UK’s experience.
M. Uccello, M. Moschetta, G. Mak, N. Martynyuk +6 more
20170 citations
Semantic Scholar
Clinical outcomes in advanced cervical cancer (CC) and endometrial cancer (EC) patients (pts) treated in phase I trials of novel molecularly targeted agents (MTAs).
A. George, V. Michalarea, S. Rafii, C. Michie +13 more
20150 citations
Semantic Scholar
Predictive factors of survival for patients with bladder cancer (BC) in phase I clinical trials.
V. Michalarea, S. Rafii, Rajiv Kumar, K. Rihawi +6 more
20140 citations
Semantic Scholar
A study of risk of infection with drugs targeting the PI3 kinase (PI3K), AKT, and mTOR pathway.
S. Rafii, D. Roda, E. Geuna, B. Rodríguez +7 more
20140 citations
Semantic Scholar
Complications of hyperglycemia in phase 1 trials targeting the PI3K-akt-mTOR (PAM) pathway.
E. Geuna, D. Roda, S. Rafii, B. Jímenez +7 more
20140 citations
Semantic Scholar
863PPREDICTIVE FACTORS OF SURVIVAL FOR PATIENTS WITH BLADDER CANCER (BC) IN PHASE I CLINICAL TRIALS.
V. Michalarea, S. Rafii, Rajiv Kumar, K. Rihawi +6 more
2014Annals of Oncology0 citations Open access
Semantic Scholar
What factors influence advanced ovarian cancer patient (AOC pt) outcomes to phase I trial treatments
T. Yap, A. George, C. Michie, M. Wong +13 more
20140 citations
Semantic Scholar
A retrospective study of inflammatory breast cancer patients from seven hospitals in the United Kingdom.
S. Rafii, C. Poole, A. Francis, S. Chaudhri +1 more
20120 citations
Semantic Scholar
the Breast Cancer Association Consortium Five Polymorphisms and Breast Cancer Risk : Results from Updated
M. Gaudet, R. Milne, A. Cox, N. Camp +108 more
20090 citations
Semantic Scholar
An investigation of apoptosis gene polymorphisms in prostate cancer
S. Rafii, G. Macpherson, Daniel Connley, F. Hamdy +3 more
20060 citations
Semantic Scholar
Mitotic defect in XRCC3 variant T241M in relation to cancer susceptibility
A. Lindh, N. Schultz, S. Rafii, A. Cox +1 more
20050 citations
Semantic Scholar
Interaction between various methods of weed control and increased fertilizer with different wheat cultivars in the Islamic Republic of Iran.
S. Rafii
19930 citations
Semantic Scholar

Frequent co-authors

Invite them to SciRah by sharing their profile.

J. de Bono×12
Invite
J. de Bono — researcher profile on SciRah
L. Molife×12
Invite
L. Molife — researcher profile on SciRah
T. Yap×10
Invite
T. Yap — researcher profile on SciRah
S. Kaye×9
Invite
S. Kaye — researcher profile on SciRah

×9

Invite

U. Banerji — researcher profile on SciRah

Invite

A. Cox — researcher profile on SciRah

Invite

E. Geuna — researcher profile on SciRah

Invite

K. Rihawi — researcher profile on SciRah

Susana Banerjee×6

Invite

Susana Banerjee — researcher profile on SciRah

Invite

D. Roda — researcher profile on SciRah

V. Michalarea×5

Invite

V. Michalarea — researcher profile on SciRah

Invite

Z. Wainberg — researcher profile on SciRah